Union Bancaire Privee UBP SA Purchases New Position in Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH)

Union Bancaire Privee UBP SA acquired a new stake in shares of Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) (TSE:AUP) during the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm acquired 13,000 shares of the biotechnology company’s stock, valued at approximately $108,000.

A number of other institutional investors have also recently added to or reduced their stakes in the business. State Street Corp increased its stake in shares of Aurinia Pharmaceuticals by 2.3% during the 3rd quarter. State Street Corp now owns 2,945,060 shares of the biotechnology company’s stock worth $21,587,000 after purchasing an additional 64,949 shares during the last quarter. Barclays PLC boosted its holdings in Aurinia Pharmaceuticals by 187.6% in the third quarter. Barclays PLC now owns 219,331 shares of the biotechnology company’s stock worth $1,607,000 after purchasing an additional 143,072 shares in the last quarter. Connor Clark & Lunn Investment Management Ltd. acquired a new position in Aurinia Pharmaceuticals during the third quarter worth $3,330,000. Charles Schwab Investment Management Inc. raised its holdings in Aurinia Pharmaceuticals by 13.7% during the third quarter. Charles Schwab Investment Management Inc. now owns 744,050 shares of the biotechnology company’s stock valued at $5,454,000 after buying an additional 89,940 shares in the last quarter. Finally, PDT Partners LLC raised its holdings in Aurinia Pharmaceuticals by 76.0% during the third quarter. PDT Partners LLC now owns 301,553 shares of the biotechnology company’s stock valued at $2,210,000 after buying an additional 130,204 shares in the last quarter. 36.83% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

Separately, StockNews.com downgraded Aurinia Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a research note on Wednesday, February 19th.

Aurinia Pharmaceuticals Trading Down 0.2 %

NASDAQ:AUPH opened at $8.03 on Wednesday. The company’s 50 day moving average is $8.27 and its 200-day moving average is $7.75. The company has a quick ratio of 5.11, a current ratio of 5.60 and a debt-to-equity ratio of 0.17. Aurinia Pharmaceuticals Inc. has a 12 month low of $4.71 and a 12 month high of $10.67. The firm has a market cap of $1.15 billion, a price-to-earnings ratio of -53.53 and a beta of 1.22.

Aurinia Pharmaceuticals Company Profile

Aurinia Pharmaceuticals Inc, a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies to treat various diseases with unmet medical need in the United States. It offers LUPKYNIS for the treatment of adult patients with active lupus nephritis. It has a collaboration and license agreement with Otsuka Pharmaceutical Co, Ltd.